We validated on-target effects of these agents both in vitro and in vivo and the ability of both drugs to suppress primary tumor growth while on-treatment, yet demonstrated that MEK inhibition alone consistently resulted in measurable altered MOC cell viability and function with little effect following mTOR inhibition. Here, MAP2K7 is linked to neoplasm.